Staff editor
Bacteria are critical in determining the outcome of surgical procedure. We talked about this with James Kinross from the Imperial College London.
The microbiome may be a source for biomarkers leading to therapeutic discoveries and diagnostics. We discuss it with Emily Hollister, Vice President of Diversigen.
Richard Ellis, Head of Business Development at Biose, explains how CDMO companies assist start-ups in bringing live biotherapeutic products to the market.
Researchers from the University of Trento have found that specific changes in gut microbiota composition are associated with colorectal cancer.
What characteristics will the probiotics of the future have? We asked Antonio Gasbarrini, director of CEMAD at the Policlinico Gemelli.
Travis Whitfill, Co-Founder and CSO of Azitra, explains how Staphylococcus epidermidis-based products may treat various skin conditions and diseases.
Alan G. Wade, the founder of CPS Research, talks about how they analyze the microbiota to assess the impact of probiotics on health.
In precision cancer care, the microbiota cannot be put aside. We talked about this with James Kinross from the Imperial College London.
Antonio Gasbarrini from the Gemelli Hospital in Rome explains how the modulation of the intestinal microbiota is entering medicine.
Probiotics: 2019 will be crucial for scientific and regulatory aspects with help coming also from Venture Capital. Denise Kelly from Seventure talks about it.
